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In this issue of Cancer Cell, Qi et al. report a novel mechanism by which HIF-1a synergizes with a tissue-
specific transcription factor, FoxA2, to promote a transcriptional program that supports prostate tumor
formation and progression.Cellular exposure to hypoxia (low O2)
occurs frequently in various human
pathologies, including tumorigenesis
(Bertout et al., 2008). During solid tumor
formation, hypoxic areas can arise due
to insufficient vascularization of rapidly
growing lesions. In response to hypoxic
stress, tumor cells initiate numerous
changes in gene expression, primarily
via stabilization of the hypoxia-inducible
factors (HIFs) HIF-1a and HIF-2a
(Semenza, 2008). Under normoxic condi-
tions, HIFa transcription factors are ubiq-
uitylated by the von Hippel-Lindau (VHL)-
E3 ligase complex and rapidly degraded
by the 26S proteasome. Ubiquitylation of
HIFs is mediated by O2-dependent prolyl
hydroxylases (PHDs). O2 depletion inacti-
vates PHDs and prevents ubiquitylation
of HIF. Stabilized HIF-1a and HIF-2a
then dimerize with their constitutively
expressed partner HIF-1b, also known
as ARNT (aryl hydrocarbon receptor
nuclear translocator), and accumulate in
the nucleus where they bind hypoxia-
responsive elements (HREs) located in
the promoter or enhancer regions of
target genes. HIF target genes regulate
multiple aspects of tumorigenesis, includ-
ing angiogenesis, metabolism, migration,
and invasion (Bertout et al., 2008).
Recently, several studies have demon-
strated that HIFa regulation in tumors is
not limited to low O2-dependent stabiliza-
tion but can also be modulated in some
cancers by oncogenic Ras signaling and
other stimuli (Blum et al., 2005; Kikuchi
et al., 2009). One prevalent tumor associ-
ated with elevated HIFa activity is pros-tate cancer, which expresses elevated
HIF-1a protein compared with normal
prostate epithelia and benign hyperpla-
sias (Zhong et al., 2004). In prostate
tumors, HIFa stability is regulated by
multiple inputs including O2 levels and
changes in androgen signaling resulting
from loss of ERb expression, which
occurs in high-grade tumors. Initial stud-
ies suggested that O2-mediated HIF-1a
stabilization is an early event in prostate
cancer, whereas loss of ERb promotes
more advanced disease by stabilizing
HIF-1a and driving EMT in a VEGF-
dependent manner (Mak et al., 2010).
In this issue, Qi et al. (2010) propose a
novel O2-dependent mechanism wherein
HIF-1a cooperates with the forkhead
box transcription factor FoxA2 to stimu-
late a transcriptional program that facili-
tates neuroendocrine prostate tumor
initiation and metastasis. The neuroendo-
crine phenotype is found in more than
30% of prostate cancers and is associ-
ated with a poor clinical outcome. In
tumors, HIFs regulate transcription both
independently and via crosstalk with
factors widely expressed in human tis-
sues, including Notch, c-Myc, and p53
(Gordan et al., 2008). Importantly, Qi
et al. have found that in addition to modu-
lating these commonly expressed factors,
HIF-1a alsomediates tissue-specific tran-
scription by interacting with FoxA2, which
is selectively expressed in neuroendo-
crine tumor tissues.
Qi et al. (2010) used the murine trans-
genic TRAMP model of metastatic pros-
tate tumors, which is driven by prostate-Cancer Cspecific expression of the SV40 T antigen,
in their study. To modulate HIF-1a levels
in the TRAMP system, the authors
silenced the ubiquitin ligase Siah2. In
general, Siah2 controls stability of PHDs,
which in turn regulate the stability of
HIFs (Nakayama et al., 2004). Thus,
silencing Siah2 increases HIFa degrada-
tion. Neuroendocrine prostate carcinoma
formation was significantly decreased in
the TRAMPtg/Siah2/ mice compared
to TRAMPtg/Siah2+/+ and TRAMPtg/
Siah2+/ animals (Figure 1). Metastases to
liver, lungs, and lymph nodes were also
dramatically decreased in the TRAMPtg/
Siah2/ mice. By using in vitro binding
assays and coimmunoprecipitations, the
authors determined that under hypoxic
conditions, FoxA2, ARNT, and HIF-1a
interacted directly in order to synergisti-
cally promote transcription via recruit-
ment of the coactivator p300. Interest-
ingly, a limited subset of HIF-1a target
genes were specifically upregulated by
FoxA2 cooperation including Hes6, Sox9,
and Jmjd1a (Figure 1; Qi et al., 2010).
Other HIF-1a targets like Glut-1 and
VEGF were unaffected. Expression of
Hes6, Sox9, and Jmjd1a promoted
anchorage-independent growth in soft
agar as well the development of a
hypoxia-dependent neuroendocrine phe-
notype in prostate carcinomas. To deter-
mine the importance of Hes6, Sox9, and
Jmjd1a expression in vivo, the authors
expressed these proteins, individually or
together, in TRAMP tumor cells while
inhibiting Siah2 with the ectopically
expressed peptide inhibitor PHYL. Theseell 18, July 13, 2010 ª2010 Elsevier Inc. 3
Figure 1. The Effects of Siah2 Inhibition and HIF
Stabilization on Prostate Cancer Formation
Deletion of Siah2 results in decreased HIFa and HIF target
(Hes6, Sox9, Jmjd1a) expression in the TRAMP model of
prostate cancer. HIF-1a synergizes with the neuroendo-
crine-specific transcription factor FoxA2 to regulate tran-
scription of these genes and drive both tumorigenesis
and the neuroendocrine phenotype in a hypoxia-dependent
manner.
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Previewscells were injected into the prostates
of mice. Coexpression of all three
genes rescued tumorigenesis in
these animals although individual
expression of the targets did not.
These data suggest that the HIF-
1a/FoxA2-mediated transcriptome
might contribute to tumor formation
and progression through simulta-
neous activation of multiple path-
ways. Further experiments revealed
that Siah2, FoxA2, Hes6, and Sox9
expression were elevated in high-
grade human prostate cancers, that
the neuroendocrine phenotype can
be triggered by hypoxia, and that
this phenotype is associated with
metastatic disease. Immunohisto-
chemistry analysis showed that
neuroendocrine markers were coex-
pressed with HIF-1a, FoxA2, Hes6,
and Sox9 in advanced human pros-
tate cancer tissue samples.
Several important questions
emerge from these findings. (1)
Is the mechanism of cooperation
between HIF-1a and tissue-specific
transcription factors common to
other tumors? (2) What other tissue-
specific transcription factors interact
with HIF-1a to modulate tumorigenictranscription in human cancers? (3) Is
there a specific relationship between HIF
and Fox family transcription factors that
supports tumor formation? (4) Does
HIF-2a also synergize with Fox family
members in some tumors? Recent find-
ings suggest that HIF and Fox transcrip-
tion factors coregulate tumorigenesis in
other tissues including breast and hepatic
cancers (Xia et al., 2009). Additionally, it is
known that the effect of HIFa isoforms
differs between tumor types, with some
tumors utilizing HIF-1a-dependent path-4 Cancer Cell 18, July 13, 2010 ª2010 Elseviways and others requiring HIF-2a and its
downstream effectors (Gordan et al.,
2008). Thus, it is possible that the mecha-
nism proposed here by Qi et al. (2010)
is widespread in tumors but that the
particular isoforms and family members
involved are tissue type specific.
With this work, Qi et al. (2010) have
further developed a molecular under-
standing of neuroendocrine prostate
carcinoma. Moreover, evaluation of the
pathways identified in their studies will
provide invaluable information in theer Inc.development of targeted therapeu-
tics for prostate cancer. Their findings
have also raised questions about the
role of synergistic HIFa-dependent
transcription in other tumor contexts.
Hopefully, the identification of addi-
tional interacting factors that syner-
gize with HIFa in a tissue-specific
manner will help elucidate meaningful
druggable targets for treatment of
prostate and other cancers.
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